Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of April 2024, filed on April 16, 2024, by Enlivex Therapeutics Ltd., an Israeli company. The filing primarily serves to disclose a significant clinical trial development regarding the company's lead product candidate, AllocetraTM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed is regulatory authorization for clinical trial expansion:
- The Danish Medicines Agency authorized the expansion of Enlivex's multi-country, randomized, controlled Phase I/II trial into Denmark.
- The trial evaluates AllocetraTM in up to 160 patients suffering from moderate to severe knee osteoarthritis.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the inherent uncertainties of clinical trials. The document incorporates a press release (Exhibit 99.1) as the primary source of the announcement.
Key Facts for Investor Verification
- Confirm the specific timeline for patient enrollment in the newly authorized Danish sites.
- Verify the total budget and funding status required to support the expanded trial scope.
- Review the full text of the press release (Exhibit 99.1) for detailed trial design parameters.
- Monitor subsequent filings for any updates on patient recruitment rates or interim data readouts.